Vendor Intelligence Report: Guangzhou Aoyu

Published 2 Jul 2026. 19-page investigative report on who is behind Guangzhou Aoyu: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Guangzhou Aoyu is 3 pass / 3 fail, for a 50% overall pass rate. The record is narrow rather than catalog-wide: Finnrick coverage is limited to Tirzepatide, and the split is uneven enough that this vendor is a poor directional choice for that product unless the incoming lot is independently tested before use. The report also shows why the rating is sensitive to stricter Finnrick grading, so buyers should not treat a single headline score as stable manufacturing control.

Guangzhou Aoyu is not a pure ghost vendor. The peptide-facing storefront sits on GlobalSources and displays a USCC, Chinese name, Guangzhou address, and marketplace contact point. But the same profile mixes small-company fields with large-manufacturer language, including R&D and factory-scale claims that the report checks against the vendor’s own platform records.

The corporate trail is the sharper issue. Older Aoyu-branded profiles exist, but they point to phone cases, lanyards, promotional accessories, and inflatable toys rather than peptides. That makes the long-experience story look less like verified peptide tenure and more like brand-name reuse across unrelated product lines unless the seller can document continuity.

The promotion sweep is comparatively clean: investigators found no searched X, coupon-page, or Reddit affiliate network for Guangzhou Aoyu. That reduces hype-network risk, but it does not offset the lab split, missing credential stack, absent visible peptide leadership, and platform-only infrastructure.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data for the single tested product, including per-product detail, sparkline, and methodology-divergence chart
  • GlobalSources profile captures showing the USCC, Chinese name, address, staffing fields, capitalization, and manufacturer-scale claims
  • Cross-platform Aoyu identity matrix comparing GlobalSources, GoldSupplier, TradeIndia, and AoyuToys records
  • Credential and export-compliance review covering import/export-license status and missing GMP/ISO evidence
  • Personnel, address, and contact-visibility assessment, including the boundary around the Vicky Huang phone-case profile
  • Promotion-footprint sweep across X, web coupon pages, and Reddit, with platform limits and open registry, payment, and customs leads

Risk assessment

  • Tirzepatide quality-control risk — high: Tirzepatide: Finnrick record shows 6 tests, 3 pass / 3 fail, and a current rating of 70.4%; no other Guangzhou Aoyu product has a Finnrick record.
  • Corporate-identity and brand-confusion risk — high: Peptide profile registered 2025-09-24 while Aoyu-named profiles from 2013/2014 sell phone cases and lanyards; no canonical official channel list or continuity proof was found.
  • Manufacturing-claim verification risk — high: GlobalSources claims 100 R&D technicians and a 5,000 sqm factory while the same profile reports 5-9 employees and under US$50k capitalization; no leadership or R&D personnel were identified.
  • Export-compliance and certification risk — medium: No GMP/ISO/product certifications were located and GlobalSources records Import & Export License: No despite an export-heavy sales claim; no vendor-specific enforcement was found in this run.